Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 1339 results for 0

  1. Laparoscopic laser myomectomy (IPG23)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

  2. Obesity: identification, assessment and management (CG189)

    This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.

  3. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  4. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

    Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.

  5. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

  6. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

  7. Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (IPG539)

    Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.

  8. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  9. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 and over. It describes high-quality care in priority areas for improvement.

  10. Fasciotens for abdominal wall closure (MIB321)

    NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .

  11. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.

  12. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

  13. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose

  14. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  15. Guselkumab for treating moderate to severe plaque psoriasis (TA521)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.